Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients

Keyphrases

• Drug Sensitivity 100%
• FMS-like Tyrosine Kinase 3 (FLT3) 100%
• Acute Myeloid Leukemia 100%
• Leukemia Patients 100%
• FLT3 mutation 100%
• Genomic Markers 100%
• Midostaurin 100%
• FLT3-ITD 66%
• Negative Samples 33%
• Overexpression 16%
• Malignancy 16%
• Genetic Modification 16%
• FDA-approved Drugs 16%
• Differentially Expressed 16%
• RNA Sequencing (RNA-seq) 16%
• Standard of Care 16%
• Response Predictors 16%
• TP53 mutation 16%
• Oncogene 16%
• Identified Genes 16%
• Induction Chemotherapy 16%
• KRAS mutation 16%
• Biological Factors 16%
• Targeted Sequencing 16%
• MAPK-ERK Signaling 16%
• Relapsed or Refractory Acute Myeloid Leukemia 16%
• FLT3 Inhibitor 16%
• Nucleophosmin 1 (NPM1) 16%
• DNMT3A 16%
• ERK Cascade 16%
• Raf-MEK-ERK 16%
• Sensitive Sample 16%
• Ex Vivo Drug Sensitivity 16%

Medicine and Dentistry

• Drug Sensitivity 100%
• Acute Myeloid Leukemia 100%
• Midostaurin 100%
• Cancer 16%
• Ex Vivo 16%
• RNA Sequence 16%
• Mitogen-Activated Protein Kinase 16%
• Induction Chemotherapy 16%
• Oncogene 16%
• Ras Signaling 16%
• NPM1 16%
• DNA Methyltransferase 3A 16%
• Biological Factor 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Midostaurin 100%
• Chemotherapy 16%
• RNA-Sequencing 16%
• Biological Factor 16%
• DNA Methyltransferase 3A 16%